The research showed a statistically significant improvement in overall quality of life in as early as three weeks in patients administered the drug.
Ulcerative colitis is a form of inflammatory bowel disease. Asacol is indicated for the treatment of mildly to moderately active UC and for the maintenance of remission of UC. Improved quality of life with Asacol had not previously been evaluated.
“The goals of UC therapy are to treat active disease and prevent relapse in order to improve quality of life, and now the data tell us that Asacol does, in fact, improve quality of life for patients, as quickly as three weeks from the start of therapy,” said Jan Irvine, head, Division of Gastroenterology, St. Michael’s Hospital, Toronto.
This data analysis was based on results from two phase III studies sponsored by Procter & Gamble.